By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Neurodegenerative Diseases. According to news reporting originating in Boston, Massachusetts, by NewsRx journalists, research stated, "Outside of their uses in drug development and clinical research trials, the current clinical value of performing any type of formal biomarker testing for the diagnosis or exclusion of Alzheimer's disease (AD) is controversial, and most biomarker tests for AD are not covered by public or private insurers. This situation raises the issue of how insurers determine whether there is 'adequate' evidence to justify a positive coverage determination in this area."
The news reporters obtained a quote from the research from Institute for Technology Assessment, "This article, a focused condensation of a larger white paper, is the product of an initiative led by the Institute for Clinical and Economic Review to convene a multiple-stakeholder AD Diagnostics Policy Development Group composed of patient advocates, clinicians, clinical researchers, manufacturers, and insurers. The larger white paper was the basis for the evidence review presented to the Medicare Evidence Development and Coverage Advisory Committee meeting on January 30, 2013, as part of its deliberations on positron emission tomography-amyloid imaging. Herein we focus on the description of the core elements of what insurers will be looking for in evidence on all potential diagnostic tests for AD."
According to the news reporters, the research concluded: "Corresponding research recommendations are also included, framed to serve as a guide for future AD diagnostics research."
For more information on this research see: Biomarker tests for the diagnosis of Alzheimer's disease: Generating evidence to inform insurance coverage determinations. Alzheimers & Dementia, 2013;9(6):745-752. Alzheimers & Dementia can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA (see also Neurodegenerative Diseases).
Our news correspondents report that additional information may be obtained by contacting S.D. Pearson, Massachusetts General Hospital, Inst Technol Assessment, Inst Clin & Econ Review, Boston, MA 02114, United States. Additional authors for this research include D.A. Ollendorf and J.A. Colby.
Keywords for this news article include: Boston, Dementia, Tauopathies, Massachusetts, United States, Brain Diseases, Alzheimer Disease, North and Central America, Neurodegenerative Diseases, Central Nervous System Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC